[Skip to Navigation]
January 2019

Dupilumab Treatment for Generalized Prurigo Nodularis

Author Affiliations
  • 1Department of Dermatology, University of California, San Francisco, San Francisco
JAMA Dermatol. 2019;155(1):118-120. doi:10.1001/jamadermatol.2018.3912

Generalized prurigo nodularis is a severe and widespread morphologic manifestation of chronic pruritus.1 This condition is challenging to treat and results in a high burden of disease.1 We examined the effectiveness of the interleukin (IL) 4 receptor α inhibitor dupilumab as a novel treatment option for generalized prurigo nodularis.

Add or change institution